Literature DB >> 12663807

Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.

Stuart Prince1, Sinead Keating, Ceri Fielding, Paul Brennan, Eike Floettmann, Martin Rowe.   

Abstract

Epstein-Barr virus (EBV) is a potent growth-transforming agent of human B cells. It has previously been shown that viral latent membrane protein 1 (LMP1) is essential for EBV-induced transformation of normal B cells and contributes to maintenance of latency in vitro. Using the EBV-positive Burkitt's lymphoma line P3HR1-c16, which lacks LMP1 during latency and which can readily be activated into virus-productive lytic cycle, we found that LMP1 inhibits lytic cycle induction via the transcription factor NF-kappa B. In addition, LMP1 inhibits lytic cycle progress via two distinct NF-kappa B-independent mechanisms: one involving the cytosolic C-terminal activating regions and the other involving the transmembrane region of LMP1. These findings indicate that in B cells EBV self-limits its lytic cycle via three distinct LMP1-mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663807      PMCID: PMC152124          DOI: 10.1128/jvi.77.8.5000-5007.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.

Authors:  E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections.

Authors:  J Webster-Cyriaque; J Middeldorp; N Raab-Traub
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state.

Authors:  N S Prang; M W Hornef; M Jäger; H J Wagner; H Wolf; F M Schwarzmann
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

6.  Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

Authors:  O Gires; U Zimber-Strobl; R Gonnella; M Ueffing; G Marschall; R Zeidler; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

7.  Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.

Authors:  E Kilger; A Kieser; M Baumann; W Hammerschmidt
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

8.  The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.

Authors:  B D'Souza; M Rowe; D Walls
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Authors:  O Devergne; E Hatzivassiliou; K M Izumi; K M Kaye; M F Kleijnen; E Kieff; G Mosialos
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

10.  Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts.

Authors:  Z He; B Xin; X Yang; C Chan; L Cao
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

View more
  32 in total

1.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 2.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

3.  Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production.

Authors:  Nazmul Ahsan; Teru Kanda; Kazuo Nagashima; Kenzo Takada
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.

Authors:  Wei Yue; Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.

Authors:  Katerina Vrzalikova; Martina Vockerodt; Sarah Leonard; Andrew Bell; Wenbin Wei; Alexandra Schrader; Kenneth L Wright; Dieter Kube; Martin Rowe; Ciaran B Woodman; Paul G Murray
Journal:  Blood       Date:  2011-03-16       Impact factor: 22.113

6.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

7.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

8.  IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Authors:  Loránd L Kis; Daniel Salamon; Emma K Persson; Noémi Nagy; Ferenc A Scheeren; Hergen Spits; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  An in vitro system for studying murid herpesvirus-4 latency and reactivation.

Authors:  Janet S May; Neil J Bennett; Philip G Stevenson
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

10.  Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds.

Authors:  Giulia Matusali; Giuseppe Arena; Alessandra De Leo; Livia Di Renzo; Elena Mattia
Journal:  Mol Cancer       Date:  2009-03-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.